POSTN and asthma: Several studies have evaluated omalizumab effectiveness in treating severe asthma; a randomized controlled trial discovered that severe asthma patients with high blood eosinophil counts, FeNO levels, and serum periostin experienced a significant reduction in exacerbation frequency [22].